FDA re­vis­es guid­ance on biosim­i­lar pro­mo­tion­al la­bels and ad­ver­tis­ing

Fol­low­ing a re­cent move to ask Con­gress to elim­i­nate the in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars, the FDA on Wednes­day pro­posed up­dat­ed guid­ance on the la­bel­ing and ad­ver­tis­ing of bi­o­log­ics and biosim­i­lars.

The new draft of­fers re­quire­ments around the con­tent of pro­mo­tion­al com­mu­ni­ca­tions, and it fol­lows the think­ing around elim­i­nat­ing in­ter­change­abil­i­ty in sev­er­al places, chang­ing up lan­guage and lump­ing biosim­i­lars and in­ter­change­able biosim­i­lars to­geth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER